New drug combo aims to tackle tough lung cancer
NCT ID NCT05815173
First seen Jan 03, 2026 · Last updated Jun 23, 2026 · Updated 26 times
Summary
This early-stage trial is testing whether adding ladarixin to the standard drug sotorasib can help people with advanced KRAS G12C mutant non-small cell lung cancer. About 40 adults whose cancer has spread or cannot be removed will receive both pills daily. The study will first check for serious side effects, then measure how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER WITH KRAS G12C MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NYU Langone Health
RECRUITINGGarden City, New York, 11530, United States
-
NYU Langone Health
RECRUITINGMineola, New York, 11501, United States
-
NYU Langone Health
RECRUITINGNew Hyde Park, New York, 11042, United States
-
NYU Langone Health
RECRUITINGNew York, New York, 10010, United States
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
-
NYU Langone Health
RECRUITINGNew York, New York, 10017, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ladarixin and sotorasib
What this could lead to
If this combination works, it could offer a new treatment option for people with a specific type of advanced lung cancer that has not responded to other therapies.
What could go wrong
This is an early-phase trial with only 40 participants, so results may not apply to everyone. The drug combination may cause serious side effects or fail to improve outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.